Table 1.
Clinical and laboratory features associated with renal disease activity
| Feature | P value* Rise in serum creatinine (N=35) |
P value* Rise in R-SLEDAI (N=90) |
| Institution | 0.0388 | 0.1178 |
| Race | 0.0154 | 0.0800 |
| Age | 0.8346 | 0.9765 |
| Male gender | <0.0001 | 0.6360 |
| LN class | 0.0002 | 0.7791 |
| Anti-RNP | 0.6489 | 0.2299 |
| Anti-phospholipid | 0.0035 | 0.7202 |
| Anti-Sm | 0.2519 | 0.2785 |
| Anti-dsDNA | 0.3158 | 0.3118 |
| Urine casts | 0.0147 | XX |
| Haematuria | 0.0015 | XX |
| Pyuria | 0.2360 | XX |
| Proteinuria | <0.0001 | XX |
| R-SLEDAI score | <0.0001 | XX |
| Baseline serum creatinine | 0.2720 | 0.0001 |
| Oral methotrexate† | <0.0001 | 0.3138 |
| Azathioprine | 0.6454 | 0.0009 |
| Mycophenolate mofetil† | 0.0003 | 0.2364 |
| Rituximab† | <0.0001 | 0.7128 |
| Systemic steroids† | 0.0002 | 0.5716 |
Significant values are bolded.
*Χ2 (categorical) or Welch-Satterthwaite t-test (continuous). XX indicates that the variable is part of the R-SLEDAI.
†Medications are listed when the p value is significant.
LN, lupus nephritis; R-SLEDAI, renal Systemic Lupus Erythematosus Disease Activity Index.